Lenzen M J, Rosengren A, Scholte op Reimer W J M, Follath F, Boersma E, Simoons M L, Cleland J G F, Komajda M
Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Heart. 2008 Mar;94(3):e10. doi: 10.1136/hrt.2006.099523. Epub 2007 Jun 17.
This study evaluated gender differences in clinical characteristics, treatment and outcome among patients with heart failure, and to what extent these differences are due to age and differences in left ventricular (LV) function. Although gender differences are observed among heart failure patients, few studies have been adequately powered to investigate these differences.
A total of 8914 (out of 10 701) patients (47% women) from the Euro Heart Survey on Heart Failure with confirmed diagnosis of heart failure were included in the analyses.
Women were older (74.7 vs 68.3 years, p<0.001), and less often had evidence of coronary artery disease (56% vs 66%, age-adjusted odds ratio (OR) 0.62; 95% CI 0.57 to 0.68). Women were more likely to have hypertension, diabetes, or valvular heart disease. Fewer women had an investigation of LV function (59% vs 74%, age-adjusted OR 0.67; 95% CI 0.61 to 0.74), and, among those investigated, fewer had moderate/severe left ventricular systolic dysfunction (44% vs 71%, age-adjusted OR 0.35; 95% CI 0.32 to 0.39). Drugs with a documented impact on survival, that is ACE-inhibitors and beta-blockers, were given less often to women, even in the adjusted analysis (OR 0.72; 95% CI 0.61 to 0.86 and OR 0.76; 95% CI 0.65 to 0.89, respectively). 12-week mortality was similar for men and women.
Fewer women had an assessment of LV function, but, when investigated, women had better ventricular function. Women were less often treated with evidence-based drugs, even after adjustment for age and important clinical characteristics. Clinicians need to be aware of deficiencies in the treatment of women with heart failure and measures should be taken to rectify them.
本研究评估了心力衰竭患者在临床特征、治疗及预后方面的性别差异,以及这些差异在多大程度上归因于年龄和左心室(LV)功能的差异。尽管在心力衰竭患者中观察到了性别差异,但很少有研究有足够的效力来调查这些差异。
对来自欧洲心力衰竭调查的10701例患者中的8914例(47%为女性)进行分析,这些患者均确诊为心力衰竭。
女性年龄更大(74.7岁对68.3岁,p<0.001),有冠状动脉疾病证据的比例更低(56%对66%,年龄调整优势比(OR)0.62;95%置信区间0.57至0.68)。女性更易患高血压、糖尿病或心脏瓣膜病。接受LV功能检查的女性较少(59%对74%,年龄调整OR 0.67;95%置信区间0.61至0.74),在接受检查的患者中,中度/重度左心室收缩功能障碍的女性更少(44%对71%,年龄调整OR 0.35;95%置信区间0.32至0.39)。即使在调整分析中,对生存有明确影响的药物,即血管紧张素转换酶抑制剂和β受体阻滞剂,给予女性的频率也更低(OR分别为0.72;95%置信区间0.61至0.86和OR 0.76;95%置信区间0.65至0.89)。男性和女性的12周死亡率相似。
接受LV功能评估的女性较少,但在接受检查时,女性的心室功能更好。即使在调整年龄和重要临床特征后,女性接受循证药物治疗的频率也较低。临床医生需要意识到心力衰竭女性患者治疗方面的不足,并应采取措施加以纠正。